Clearside reports positive safety results from OASIS Phase 1/2a trial of CLS-AX for wet AMD; dose escalation to 0.5 mg

Clearside Biomedical, Inc.

Cohort 2 (0.1 mg CLS-AX, n=5) well-tolerated: no serious adverse events, no treatment-related AEs, no vitreous dispersion.
Combined Cohorts 1 & 2 (n=11): 36% of patients had no retreatments for ≥3 months; 55% for ≥2 months.
Mean best corrected visual acuity (BCVA) and central subfield thickness (CST) were stable in the first two cohorts.
Safety Monitoring Committee approved escalation to Cohort 3 (0.5 mg CLS-AX); patient screening has begun.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.